European Network on Optimizing Treatment With Therapeutic Antibodies in Chronic Inflammatory Diseases: Overview, Progress and Perspectives.

Konstantin Tachkov, Merita Rumano, James Bluett, Nataša Bogavac-Stanojević, Erwin Dreesen, Mehmet Itik, Georgios Kararigas, Paweł Kawalec, Marlene Santos, Silje Skrede, Guenka Petrova, Denis Mulleman

Journal: Clinical and translational science 2026;19(6):e70643

PMID: 42321148

Free Full Text on PubMed Central View on PubMed

Abstract

Treatment of chronic inflammatory diseases has been revolutionized with the introduction of targeted therapies using therapeutic antibodies. However, a large proportion of patients do not respond to treatment, or they lose response over time. To overcome this challenge, researchers have started to investigate strategies for treatment optimization, based on the development of patient stratification tools and therapeutic drug monitoring (TDM). The aim of the COST Action European Network on Optimizing Treatment with Therapeutic Antibodies in chronic inflammatory diseases (ENOTTA) is to create an interdisciplinary, pan-European network to defragment and structure scientific research in this field. Through the network, ENOTTA will facilitate the implementation of tools for patient stratification, as well as individualized (TDM-guided) approaches. These strategies should be cost-effective and provide therapeutic antibody treatment optimization for the treatment of chronic inflammatory diseases. This article highlights the key achievements of the ENOTTA consortium to date.

Address: Department of Organization and Economy of Pharmacy, Medical University Sofia, Sofia, Bulgaria.; Department of Biology, Faculty of Natural Sciences, University of Tirana, Tirana, Albania.; Faculty of Medicine, University of Medicine in Tirana, Tirana, Albania.; Versus Arthritis Centre for Genetics and Genomics, Centre for Musculoskeletal Research, the University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.; NIHR Manchester Biomedical Research Centre, Manchester Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.; University of Belgrade, Faculty of Pharmacy, Belgrade, Serbia.; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.; Department of Aerospace Engineering, Dokuz Eylul University, Izmir, Türkiye.; Department of Basic and Clinical Sciences, Medical School, University of Nicosia, UNIC Athens, Athens, Greece.; Department of Nutrition and Drug Research, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Medical College, Kraków, Poland.; REQUIMTE/LAQV, Escola Superior De Saúde, Instituto Politécnico Do Porto, Porto, Portugal.; Molecular Oncology & Viral Pathology, IPO-Porto Research Center, Portuguese Institute of Oncology, Porto, Portugal.; Department of Clinical Science, Faculty of Medicine, University of Bergen, Bergen, Norway.; Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway.; Department of Organization and Economy of Pharmacy, Medical University Sofia, Sofia, Bulgaria.; Medical University Sofia, Scientific Institute for Innovative Medical Sciences, Sofia, Bulgaria.; Center for Molecular Biophysics, UPR CNRS 4301, Nanomedicines and Nanoprobes Department, University of Tours, Tours, France.; Department of Rheumatology, University Hospital Center of Tours, Tours, France.

DOI: 10.1111/cts.70643

Link outs

Free resources

Full Text Sources:

https://pmc.ncbi.nlm.nih.gov/articles/pmid/4232114...

Subscription / membership required

Full Text Sources:

https://doi.org/10.1111/cts.70643

MeSH Terms: Humans, Inflammation, Chronic Disease, Europe, Drug Monitoring, Antibodies, Monoclonal